Applied Therapeutics, Inc. - Common Stock (APLT)

Competitors to Applied Therapeutics, Inc. - Common Stock (APLT)

Alnylam Pharmaceuticals, Inc. 

Alnylam is pioneering RNA interference therapies, targeting rare diseases, including inherited metabolic disorders that may overlap with some of Applied Therapeutics' focuses. Both companies thrive on innovation and addressing unmet medical needs, creating direct competition in the rare disease space. However, Alnylam's established clinical data and successful commercialization of their therapies provide them with a competitive edge.

Amgen Inc. 

Amgen is a biotechnology company that develops therapies for a variety of diseases, including metabolic disorders. As both Applied Therapeutics and Amgen focus on innovative treatments, they compete in the same therapeutic areas where Applied Therapeutics is developing its lead candidates. Amgen's extensive product portfolio, established market presence, and significant resources give it a competitive advantage, positioning it as a leader in the biotechnology space.

Catalent, Inc. 

Catalent provides advanced delivery technologies, development, and manufacturing solutions for drugs, including biologics and small molecules. While Applied Therapeutics is a research-focused biotech company, the competition arises particularly in the contract development and manufacturing sector. Catalent's significant scale and experience in manufacturing and delivering biologics give it an edge, positioning them as a leader in this space.

Eli Lilly and Company 

Eli Lilly is a major player in the pharmaceutical industry with a strong emphasis on diabetes and metabolic diseases, which overlaps with some of Applied Therapeutics' areas of interest. While Applied Therapeutics is focused on niche indications, Eli Lilly's financial strength and established market presence allow it to conduct robust clinical trials and launch new therapies efficiently, making it a formidable competitor in the market.

Moderna, Inc. 

Moderna is known for its mRNA technology platform, which initially evolved through the COVID-19 vaccine success, but is now investigating various therapeutic areas including metabolic diseases. While Applied Therapeutics takes a more traditional biotech approach, Moderna's technological advances and agile R&D capabilities give it a significant advantage in rapid development and scalability.